+39 02 610346.1 - info@newron.com

Investors and Media

Investors and Media

Newron Pharmaceuticals is headquartered in Bresso, Italy and its shares are listed on SIX Swiss Exchange under the ticker symbol NWRN. Newron is committed to providing reliable and transparent information about our business in an open and timely manner. This area contains investment and shareholder information, including our latest share price, key financial data and presentations and webcasts.

 

Newron newssee all

April 11 2017

Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada

April 10 2017

ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease

 

April 05 2017

Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia

March 28 2017

Newron Shareholders Confirm Company Management

 

March 25 2017

Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia

 

Stock information

Download centre

Email alerts

 

 

 

 

 

Upcoming Eventssee all

Investora 2017

Sept. 20-21, 2017 - Zurich, CH

Jefferies 2017 Global Healthcare Conference

June 6-9, 2017 at the Grand Hyatt in New York City

Bio€quity Europe 2017

May 22-23 - Paris, France